Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

home / peer-exchange / advances-in-cdk4-6-inhibitor-use-in-high-risk-early-breast-cancer-2024-updates

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel in a discussion highlighting recent updates for use of CDK4/6 inhibitors in high-risk early breast cancer.

Episodes

June 26th 2024EP. 1: Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.

June 26th 2024EP. 2: Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.

July 8th 2024EP. 3: Outcomes from NATALEE and MonarchE

Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.

July 8th 2024EP. 4: Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of experts discuss sequencing considerations with CDK4/6.

July 10th 2024EP. 5: Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

July 10th 2024EP. 6: Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.

July 29th 2024EP. 7: Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

Dr. Rugo details her management strategy in regards to GI toxicities.

July 29th 2024EP. 8: Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

A medical expert navigates toxicity management in patients being treated with ribociclib.

July 29th 2024EP. 9: Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

July 29th 2024EP. 10: How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

August 5th 2024EP. 11: Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

August 5th 2024EP. 12: Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

August 12th 2024EP. 13: ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Kirollos S. Hanna, PharmD, BCPS, BCOP;Hope Rugo, MD;Joyce O’Shaughnessy, MD;Naomi Dempsey, MD

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions